Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer

Lung Cancer

Volumn 14, Issue 1, 1996, Pages 119-134

  Perol M ^a   Guerin J C ^a   Thomas, P ^b   Poirier, R ^c   Carles, P ^d   Robinet, G ^e   Kleisbauer, J P ^b   Paillotin, D ^f   Vergnenegre A ^g   Balmes, P ^h   Touron, D ⁱ   Grivaux, M ^j   Pham, E ^k  

^a CROIX ROUSSE HOSPITAL   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c CENTRE HOSPITALIER   (France)

^d CHU PURPAN   (France)

^e CHU MORVAN   (France)

^f Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^g Hopital du Cluzeau   (France)

^h NÎMES UNIVERSITY HOSPITAL   (France)

ⁱ HAUT LÉVÊQUE HOSPITAL   (France)

^j CENTRE HOSPITALIER DE MEAUX   (France)

^k NONE

more..

Author keywords

Non small cell lung cancer; Vindesine; Vinorelbine

Indexed keywords

CISPLATIN; MITOMYCIN; NAVELBINE; VINDESINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL; VOMITING;

EID: 2542510542     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(95)00517-X     Document Type: Article

References (24)

1. Bonomi P, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602-1613.
2. Bunn PA. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 1989; 16: 10-21.
3. Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992; 10: 580-586.
4. Crawford J, O'Rourke MA. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. Semin Oncol 1994; 21 (suppl. 10): 73-78.
5. Crino L, Tonato M, Darvish S, et al. A randomized trial of 3 cisplatin-containing regimens in advanced non-small cell lung cancer: a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990; 26: 52-56.
6. Crino L, Clerici M, Figoli F, et al. Superiority of three-drug combination chemotherapy vs cisplatin-etoposide in advanced non-small cell lung cancer. A randomized trial of the Italian Oncology Group for Clinical Research. Lung Cancer 1994; 11 (suppl. 1): 472 (abstract).
7. Cros S, Wright M, Morimoto M, et al. Experimental antitumor activity of navelbine. Semin Oncol 1989; 16 (suppl. 4): 15-20.
8. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 115-119.
9. Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994; 5: 37-42.
10. Einhorn LH, Loehrer PJ, Williams SD, et al. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 1986; 4: 1037-1043.
11. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1986; 4: 702-709.
12. Furuse K, Kubota K, Kawahara M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 1994; 11: 385-391.
13. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosages schedules. Ann Intern Med 1981; 95: 414-420.
14. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14: 65-74.
15. Kosmidis P, Mylonakis N, Skarlos DV, et al. A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. Ann Oncol 1994; 5: 159-162.
16. Kris MG, Gralla RJ, Wertheim MS, et al. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 1986; 70: 1091-1096.
17. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
18. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-1374.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
20. O'Rourke M, Crawford J, Schiller J, et al. Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine* in a randomized controlled trial. Proc Am Soc Clin Oncol 1993; 12: 1148 (abstract).
21. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4: 14-22.
22. Shinkai T, Eguchi K, Sasaki Y, et al. A randomized clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1991; 27: 571-575.
23. Thomas P, Kleisbauer JP, Pérol M, et al. Cisplatin-mitomycin and vindesine in the treatment of inoperable non-small cell lung cancer. Groupe Français de Pneumo-Cancérologie. Eur J Cancer 1993; 29: 477.
24. Weick JK, Crowley J, Natale RB, et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 1991; 9: 1157-1162.